MelluG

Mellug is a biotechnology company focused on developing next-generation insulin therapies for the treatment of diabetes. The company's core technology centers on glucose-responsive insulin (GRI), often referred to as "smart insulin," which is designed to automatically activate in response to high blood glucose levels and remain inactive when glucose levels are low. This approach aims to provide more precise glycemic control while significantly reducing the risk of hypoglycemia, a common and dangerous side effect of traditional insulin therapy. Founded by Dr. Danny Chou, a leader in insulin engineering, Mellug leverages advanced chemical biology and protein engineering to create long-acting, self-regulating insulin analogs.